Dr McMillian is Vice President of Scientific and Regulatory Affairs at Invitrocue. He has more than two decades of experience in drug testing, in vitro and in vivo toxicology. Michael is leading InvitroCue’s overall work in relation to scientific strategy with focus on our drug testing services and expanding the applications of our proprietary tissue engineered models. Dr McMillian was a DABT (Year 2005 – 2015) toxicologist who headed the Toxicogenomics Group in the Preclinical Mechanistic Toxicology Program at Janssen Pharmaceuticals, Inc. – a pharmaceutical company of Johnson and Johnson – for 16 years. He spearheaded the In Vitro and In Vivo Toxicology Program for prioritization of compounds. His group had taken a broad coverage approach for toxicogenomics, utilizing over 140 paradigm toxicants to predict hepatotoxicity. He has also worked on predictive in vitro models for drug development and approaches to predict idiosyncratic toxicity. He has published more than 100 original articles, book chapters, reviews and holds several patents.

  drug testing, in vitro and in vivo toxicology, hepatotoxicity,  predictive in vitro models for drug development and approaches to predict idiosyncratic toxicity